G-CSF (Granulocyte Colony Stimulating Factors) Global Market Report 2025

Description

The G-CSF (granulocyte colony-stimulating factors) market comprises a category of colony-stimulating factors that enhance the bone marrow's capacity to generate more white blood cells. G-CSF is utilized in the treatment of patients with specific tumors, neutropenia resulting from certain chemotherapy types, or severe persistent neutropenia unrelated to cancer treatment. It is also known by other names such as Filgrastim and Granulocyte Colony-Stimulating Factor.

Key types within the G-CSF market include lenograstim, filgrastim, Pegfilgrastim, and others. Lenograstim is a glycosylated recombinant therapeutic drug that closely resembles or is identical to a naturally occurring human granulocyte colony-stimulating factor (G-CSF). The various products are available in forms such as tablets, capsules, and others, and find applications in treating oncological diseases, blood disorders, growth hormone deficiencies, chronic and autoimmune disorders, among others.

The G-CSF (Granulocyte Colony Stimulating Factors) market research report is one of a series of new reports from The Business Research Company that provides G-CSF (Granulocyte Colony Stimulating Factors) market statistics, including G-CSF (Granulocyte Colony Stimulating Factors) industry global market sizes, regional shares, competitors with a G-CSF (Granulocyte Colony Stimulating Factors) market share, detailed G-CSF (Granulocyte Colony Stimulating Factors) market segments, market trends and opportunities, and any further data you may need to thrive in the G-CSF (Granulocyte Colony Stimulating Factors) industry. This G-CSF (granulocyte colony stimulating factors) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The G-CSF (granulocyte colony stimulating factors) market size has grown steadily in recent years. It will grow from $5.5 billion in 2024 to $5.72 billion in 2025 at a compound annual growth rate (CAGR) of 3.9%. The growth in the historic period can be attributed to increase in cancer prevalence, strong economic growth in emerging markets, increased healthcare expenditure, increase in pharmaceutical R& expenditure and government initiatives.

The G-CSF (granulocyte colony stimulating factors) market size is expected to see strong growth in the next few years. It will grow to $7.19 billion in 2029 at a compound annual growth rate (CAGR) of 5.9%. The growth in the forecast period can be attributed to increasing prevalence of cancer, increasing demand for prophylaxis granulocyte colony-stimulating factor (g-CSF), rise in healthcare expenditure, high potential of emerging economies, technology advances and high penetration of the biosimilar drugs. Major trends in the forecast period include investing extensively in R&D activities for the development of effective and innovative drugs, increasing focus on M&A growth strategies, establishing strategic partnerships and developments activities in new drug developments and focusing efforts towards the production of biosimilars for neutropenia treatment to improve revenues and product offerings.

The growth of the G-CSF (granulocyte colony stimulating factor) market is significantly influenced by the increasing prevalence of cancer. Cancer, ranking as the second leading cause of death globally, accounts for approximately 1 in 6 deaths worldwide. For example, data from the American Cancer Society in January 2023 indicates that an estimated 1,958,310 new cancer cases and 609,820 cancer-related deaths are projected in the United States for the year 2023. G-CSF, a category of growth factors, plays a crucial role in generating white blood cells in the bone marrow, thereby reducing the risk of infection and sepsis. In cancer patients, G-CSF aids in accelerating recovery and decreasing mortality associated with neutropenia following cancer chemotherapy. Moreover, it has the potential to mitigate infections after specific cancer treatments. Consequently, the increasing prevalence of cancer is poised to be a driving force behind the expansion of the G-CSF market.

The anticipated rise in healthcare expenditure is expected to act as a catalyst for the future growth of the G-CSF market. Healthcare expenditure encompasses the financial outlay on various healthcare components, including medical equipment, pharmaceuticals, hospital care, physician services, and public health initiatives. The level of healthcare expenditure holds significant implications for the G-CSF market, influencing aspects such as cost-effectiveness, adoption rates, cost savings, market growth, and budgetary considerations related to G-CSF products. As evidenced by the 2021-2030 National Health Expenditure (NHE) report from the Centers for Medicare & Medicaid Services, annual national health spending is projected to witness an average increase of 5.1% between 2021 and 2030, reaching an estimated $6.8 trillion by 2030. Furthermore, Medicare expenditures are anticipated to grow at a 7.2% annual rate, and Medicaid spending is projected to increase at a 5.6% annual rate during the same period. Consequently, the upswing in healthcare expenditure emerges as a key driver for the growth of the G-CSF market.

Companies in the G-CSF (granulocyte colony stimulating factor) market are strategically emphasizing collaborations to foster innovation and expand their market share. The trend of partnerships, in-licensing, and out-licensing deals has been on the rise, with companies engaging in collaborative ventures with each other, as well as with academic and research institutions. A notable instance from 2022 involves Evive Biotech, a Singapore-based biopharmaceutical company, joining forces with the German pharmaceutical company APOGEPHA. The exclusive long-term license agreement was established for the commercialization of Efbemalenograstim alfa (F-627) in Germany and Switzerland. F-627, a novel dimeric G-CSF long-acting fusion protein without pegylation, holds promise as a significant product in the market.

Major players in the G-CSF market are actively integrating automation into their product offerings, particularly in the form of automated injection devices, to gain a competitive advantage. Automated injection devices are medical devices designed to deliver a dose of G-CSF automatically into the body at a predetermined time post-chemotherapy. A case in point is Kyowa Kirin Co. Ltd., a Japanese pharmaceutical company, which introduced G-Lasta Subcutaneous Injection 3.6 mg BodyPod in December 2022. This long-acting G-CSF preparation aims to reduce the incidence of febrile neutropenia in patients undergoing cancer chemotherapy. The automated injection device administers a G-Lasta dose approximately 27 hours after connection, eliminating the need for an additional outpatient visit the following day for G-Lasta administration.

In July 2022, Evive Biotech, a biopharmaceutical company based in Singapore, formed a partnership with APOGEPHA Arzneimittel GmbH (APOGEPHA). This collaboration enables Evive Biotech to effectively commercialize Efbemalenograstim alfa, an innovative granulocyte colony-stimulating factor (G-CSF) product aimed at boosting neutrophil production in cancer patients. APOGEPHA Arzneimittel GmbH is a pharmaceutical company located in Germany that specializes in providing G-CSF (granulocyte colony-stimulating factor).

Major companies operating in the G-CSF (granulocyte colony stimulating factors) market include Amgen Inc., Coherus Biosciences Inc., Sandoz, Biocon/Mylan, Teva Pharmaceuticals Inc., Chugai Pharma, Intalfarmaco Group, Pfizer, Sun Pharmaceutical Industries Limited, BeyondSpring Inc., Kyowa Hakko Kirin Co. Ltd, BioCad, Stada Arzneimittel, Dong-A Socio Group, Dr. Reddy's Laboratories, Celltrion Inc., Emcure Pharmaceuticals, Accord Healthcare UK, Intas Pharmaceuticals, Spectrum Pharmaceuticals, Apobiologix, Apotex Inc., Eurofarma Laboratorios, BIOPHARMA-MEA, NeoTX, AID Genomics Limited, GlaxoSmithKline plc, AstraZeneca, Merck Sharp & Dohme Corp., Julphar, Sanofi, Novo Nordisk A/S, Bayer, Kitov Pharma Limited, CureTech Ltd., Neopharma, Cipla.

North America was the largest region in the G-CSF (granulocyte colony-stimulating factors) market in 2024. The regions covered in the G-CS (granulocyte colony stimulating factors) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the G-CSF (granulocyte colony stimulating factors) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Canada, Spain

The G-CSF (granulocyte colony stimulating factors) market consists of sales of releuko, accofil, and pegylated. Values in this market are ""factory gate values,"" that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

G-CSF (Granulocyte Colony Stimulating Factors) Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on g-csf (granulocyte colony stimulating factors) market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for g-csf (granulocyte colony stimulating factors) ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The g-csf (granulocyte colony stimulating factors) market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:1) By Type: Pegfilgrastim, Lenograstim, Filgrastim, Other Types
2) By Product: Tablet, Capsule, Other Products
3) By Application: Oncological Diseases, Blood Disorders, Chronic And Autoimmune Disorders, Other Applications
Subsegments:
1) By Pegfilgrastim: Pre-filled Syringes; Vial Formulations; Biosimilars Of Pegfilgrastim
2) By Lenograstim: Injectable Formulations; Vial Formulations; Combination Therapies
3) By Filgrastim: Injectable Formulations; Pre-filled Syringes; Biosimilars Of Filgrastim
4) By Other Types: Filgrastim-sndz (Biosimilar); Novel G-CSF Products In Development; Combination Therapies With Other Growth Factors
Companies Mentioned: Amgen Inc.; Coherus Biosciences Inc.; Sandoz; Biocon/Mylan; Teva Pharmaceuticals Inc.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery format: PDF, Word and Excel Data Dashboard.

Product Code: r25659

1. Executive Summary

2. G-CSF (Granulocyte Colony Stimulating Factors) Market Characteristics

3. G-CSF (Granulocyte Colony Stimulating Factors) Market Trends And Strategies

4. G-CSF (Granulocyte Colony Stimulating Factors) Market - Macro Economic Scenario including the impact of Interest Rates, Inflation, Geopolitics and Covid And Recovery on the Market

5. Global G-CSF (Granulocyte Colony Stimulating Factors) Growth Analysis And Strategic Analysis Framework

5.1. Global G-CSF (Granulocyte Colony Stimulating Factors) PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global G-CSF (Granulocyte Colony Stimulating Factors) Market Growth Rate Analysis
5.4. Global G-CSF (Granulocyte Colony Stimulating Factors) Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global G-CSF (Granulocyte Colony Stimulating Factors) Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global G-CSF (Granulocyte Colony Stimulating Factors) Total Addressable Market (TAM)

6. G-CSF (Granulocyte Colony Stimulating Factors) Market Segmentation

6.1. Global G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Pegfilgrastim
Lenograstim
Filgrastim
Other Types
6.2. Global G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Tablet
Capsule
Other Products
6.3. Global G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Oncological Diseases
Blood Disorders
Chronic And Autoimmune Disorders
Other Applications
6.4. Global G-CSF (Granulocyte Colony Stimulating Factors) Market, Sub-Segmentation Of Pegfilgrastim, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Pre-filled Syringes
Vial Formulations
Biosimilars Of Pegfilgrastim
6.5. Global G-CSF (Granulocyte Colony Stimulating Factors) Market, Sub-Segmentation Of Lenograstim, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Injectable Formulations
Vial Formulations
Combination Therapies
6.6. Global G-CSF (Granulocyte Colony Stimulating Factors) Market, Sub-Segmentation Of Filgrastim, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Injectable Formulations
Pre-filled Syringes
Biosimilars Of Filgrastim
6.7. Global G-CSF (Granulocyte Colony Stimulating Factors) Market, Sub-Segmentation Of Other Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Filgrastim-sndz (Biosimilar)
Novel G-CSF Products In Development
Combination Therapies With Other Growth Factors

7. G-CSF (Granulocyte Colony Stimulating Factors) Market Regional And Country Analysis

7.1. Global G-CSF (Granulocyte Colony Stimulating Factors) Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global G-CSF (Granulocyte Colony Stimulating Factors) Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific G-CSF (Granulocyte Colony Stimulating Factors) Market

8.1. Asia-Pacific G-CSF (Granulocyte Colony Stimulating Factors) Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China G-CSF (Granulocyte Colony Stimulating Factors) Market

9.1. China G-CSF (Granulocyte Colony Stimulating Factors) Market Overview
9.2. China G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India G-CSF (Granulocyte Colony Stimulating Factors) Market

10.1. India G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan G-CSF (Granulocyte Colony Stimulating Factors) Market

11.1. Japan G-CSF (Granulocyte Colony Stimulating Factors) Market Overview
11.2. Japan G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia G-CSF (Granulocyte Colony Stimulating Factors) Market

12.1. Australia G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia G-CSF (Granulocyte Colony Stimulating Factors) Market

13.1. Indonesia G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea G-CSF (Granulocyte Colony Stimulating Factors) Market

14.1. South Korea G-CSF (Granulocyte Colony Stimulating Factors) Market Overview
14.2. South Korea G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe G-CSF (Granulocyte Colony Stimulating Factors) Market

15.1. Western Europe G-CSF (Granulocyte Colony Stimulating Factors) Market Overview
15.2. Western Europe G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK G-CSF (Granulocyte Colony Stimulating Factors) Market

16.1. UK G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany G-CSF (Granulocyte Colony Stimulating Factors) Market

17.1. Germany G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.2. Germany G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Germany G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France G-CSF (Granulocyte Colony Stimulating Factors) Market

18.1. France G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. France G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. France G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy G-CSF (Granulocyte Colony Stimulating Factors) Market

19.1. Italy G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.2. Italy G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.3. Italy G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain G-CSF (Granulocyte Colony Stimulating Factors) Market

20.1. Spain G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe G-CSF (Granulocyte Colony Stimulating Factors) Market

21.1. Eastern Europe G-CSF (Granulocyte Colony Stimulating Factors) Market Overview
21.2. Eastern Europe G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia G-CSF (Granulocyte Colony Stimulating Factors) Market

22.1. Russia G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America G-CSF (Granulocyte Colony Stimulating Factors) Market

23.1. North America G-CSF (Granulocyte Colony Stimulating Factors) Market Overview
23.2. North America G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA G-CSF (Granulocyte Colony Stimulating Factors) Market

24.1. USA G-CSF (Granulocyte Colony Stimulating Factors) Market Overview
24.2. USA G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada G-CSF (Granulocyte Colony Stimulating Factors) Market

25.1. Canada G-CSF (Granulocyte Colony Stimulating Factors) Market Overview
25.2. Canada G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America G-CSF (Granulocyte Colony Stimulating Factors) Market

26.1. South America G-CSF (Granulocyte Colony Stimulating Factors) Market Overview
26.2. South America G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil G-CSF (Granulocyte Colony Stimulating Factors) Market

27.1. Brazil G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East G-CSF (Granulocyte Colony Stimulating Factors) Market

28.1. Middle East G-CSF (Granulocyte Colony Stimulating Factors) Market Overview
28.2. Middle East G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa G-CSF (Granulocyte Colony Stimulating Factors) Market

29.1. Africa G-CSF (Granulocyte Colony Stimulating Factors) Market Overview
29.2. Africa G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. G-CSF (Granulocyte Colony Stimulating Factors) Market Competitive Landscape And Company Profiles

30.1. G-CSF (Granulocyte Colony Stimulating Factors) Market Competitive Landscape
30.2. G-CSF (Granulocyte Colony Stimulating Factors) Market Company Profiles
- 30.2.1. Amgen Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. Coherus Biosciences Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. Sandoz Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. Biocon/Mylan Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. Teva Pharmaceuticals Inc. Overview, Products and Services, Strategy and Financial Analysis

31. G-CSF (Granulocyte Colony Stimulating Factors) Market Other Major And Innovative Companies

31.1. Chugai Pharma
31.2. Intalfarmaco Group
31.3. Pfizer
31.4. Sun Pharmaceutical Industries Limited
31.5. BeyondSpring Inc.
31.6. Kyowa Hakko Kirin Co. Ltd
31.7. BioCad
31.8. Stada Arzneimittel
31.9. Dong-A Socio Group
31.10. Dr. Reddy's Laboratories
31.11. Celltrion Inc.
31.12. Emcure Pharmaceuticals
31.13. Accord Healthcare UK
31.14. Intas Pharmaceuticals
31.15. Spectrum Pharmaceuticals

32. Global G-CSF (Granulocyte Colony Stimulating Factors) Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The G-CSF (Granulocyte Colony Stimulating Factors) Market

34. Recent Developments In The G-CSF (Granulocyte Colony Stimulating Factors) Market

35. G-CSF (Granulocyte Colony Stimulating Factors) Market High Potential Countries, Segments and Strategies

35.1 G-CSF (Granulocyte Colony Stimulating Factors) Market In 2029 - Countries Offering Most New Opportunities
35.2 G-CSF (Granulocyte Colony Stimulating Factors) Market In 2029 - Segments Offering Most New Opportunities
35.3 G-CSF (Granulocyte Colony Stimulating Factors) Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations
36.2. Currencies
36.3. Historic And Forecast Inflation Rates
36.4. Research Inquiries
36.5. The Business Research Company
36.6. Copyright And Disclaimer